Search


News & Events
Finding new treatments for rare brain cancers in infantsThe WA Kids Cancer Centre has secured $1.1 million in funding from the Medical Research Future Fund’s (MRFF) Paediatric Brain Cancer Research Stream 2 to develop more effective and less toxic treatments for rare brain cancers in infants.

News & Events
The Kids researchers awarded Raine Medical Research Foundation fundingCongratulations to three The Kids Research Institute Australia researchers, who have been awarded funding from the Raine Medical Research Foundation.
News & Events
New imaging equipment to boost children's cancer researchA cutting edge cancer imaging facility will help specialist children's cancer researchers at Perth's Telethon Institute for Child Health Research.
Research
MEIS proteins as partners of the TLX1/HOX11 oncoproteinAberrant expression of the TLX1/HOX11 proto-oncogene is associated with a significant subset of T-cell acute lymphoblastic leukemias...
Research
Childhood and parental diagnostic radiological procedures and risk of childhood brain tumorsWe found no evidence of positive associations between risk of childhood brain tumours overall and childhood or parental pre-pregnancy radiological procedures.
Research
Parental alcohol consumption and risk of childhood acute lymphoblastic leukemia and brain tumorsChildhood acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and brain tumors (CBTs) are the leading cause of cancer death in...
Research
MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63We hypothesized that reactivation of p53 by inhibition of its negative regulator will result in p53-mediated growth arrest and apoptosis.
Research
Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.This study describes the development and molecular characterization of a panel of patient-derived infant leukemia oncogene xenografts and their sensitivity...
Research
Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphomaIL7 and glucocorticoids coordinately drive aberrant activation of PIM1 and suggests that T-ALL and T-LBL patients could benefit from PIM inhibition